Announcements Trials
Browse Landscape

Phase

Phase 2 4

Status

Recruiting 3Active not recruiting 1

Sponsor Class

OTHER 2NIH 2

Study Type

Interventional 4

Sponsor

Cancer Type

Head & Neck 4

Conditions

Carcinoma, Non-Small-Cell Lung 38Melanoma 15Neoplasm Metastasis 12Squamous Cell Carcinoma of Head and Neck 11Lung Neoplasms 11Skin Neoplasms 10Neoplasms 9Ovarian Neoplasms 8Recurrence 7Colorectal Neoplasms 7Carcinoma, Renal Cell 7Urinary Bladder Neoplasms 6Head and Neck Neoplasms 6Carcinoma, Basal Cell 6Breast Neoplasms 6Adenocarcinoma 6Uterine Cervical Neoplasms 5Triple Negative Breast Neoplasms 5Colonic Neoplasms 5Carcinoma, Squamous Cell 5Carcinoma, Merkel Cell 5Carcinoma 5Prostatic Neoplasms 4Pancreatic Neoplasms 4Mouth Neoplasms 4Glioblastoma 4Fallopian Tube Neoplasms 4Stomach Neoplasms 3Sarcoma 3Mycosis Fungoides 3

Interventions

Magnetic Resonance Spectroscopy 18pembrolizumab 16Specimen Handling 15Cisplatin 14Carboplatin 9Platinum 8Cetuximab 81,2-diaminocyclohexaneplatinum II citrate 8Radiotherapy, Intensity-Modulated 7Radiation 7Paclitaxel 7Biopsy 7Taxes 6Radiotherapy 6cemiplimab 4X-Rays 4Standard of Care 4Nivolumab 4Drug Therapy 4(225)Ac-DOTA-c(RGDyK) 4durvalumab 3Ultrasonography 3Surgical Procedures, Operative 3Sentinel Lymph Node Biopsy 3Observation 3Immunoglobulin G 3Disulfides 3ipatasertib 2Watchful Waiting 2Surveys and Questionnaires 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Mouth Neoplasms × cemiplimab × 1 year × Clear all
NCT06980038 2026-06-01

Testing Whether Cemiplimab (REGN2810) Plus CDX-1140 Given Prior to Surgery Are Better Than Cemiplimab (REGN2810) Alone in Patients With Stage III-IV Head and Neck Cancer

National Cancer Institute (NCI)

Phase 2 Recruiting
44 enrolled
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Nasopharyngeal Carcinoma, Carcinoma, Laryngeal Neoplasms, Mouth Neoplasms

NCT06448026 2026-05-20

Cemiplimab and Cetuximab Prior Salvage Surgery in Patients With Recurrent Oral Cavity Squamous Cell Carcinoma (OCSCC).

M.D. Anderson Cancer Center

Phase 2 Recruiting
17 enrolled
Head & Neck

Mouth Neoplasms

NCT07195734 2026-05-19

Testing the Addition of Chemotherapy or Chemo-Immunotherapy to the Usual Surgery for Advanced Head and Neck Cancer

National Cancer Institute (NCI)

Phase 2 Recruiting
180 enrolled
Head & Neck

Carcinoma, Laryngeal Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms

NCT04862650 2026-02-10

Cemiplimab, Low-Dose Paclitaxel and Carboplatin for the Treatment of Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck

Ohio State University Comprehensive Cancer Center

Phase 2 Active not recruiting
46 enrolled
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡